Declan G. Murphy

20.2k total citations · 8 hit papers
300 papers, 9.4k citations indexed

About

Declan G. Murphy is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Declan G. Murphy has authored 300 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Pulmonary and Respiratory Medicine, 74 papers in Surgery and 67 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Declan G. Murphy's work include Prostate Cancer Diagnosis and Treatment (153 papers), Prostate Cancer Treatment and Research (145 papers) and Radiopharmaceutical Chemistry and Applications (45 papers). Declan G. Murphy is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (153 papers), Prostate Cancer Treatment and Research (145 papers) and Radiopharmaceutical Chemistry and Applications (45 papers). Declan G. Murphy collaborates with scholars based in Australia, United Kingdom and United States. Declan G. Murphy's co-authors include Nathan Lawrentschuk, Michael S. Hofman, Damien Bolton, Marlon Perera, Nathan Papa, Daniel Christidis, Scott Williams, Anthony J. Costello, Mark Frydenberg and Rodney J. Hicks and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Declan G. Murphy

280 papers receiving 9.3k citations

Hit Papers

[177Lu]-PSMA-617 radionuclide treatment in patients with ... 2015 2026 2018 2022 2018 2016 2019 2018 2015 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
    2018 815 citations Michael S. Hofman, Sue Ping Thang et al. profile →
  2. Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
    2016 744 citations Marlon Perera, Nathan Papa et al. European Urology profile →
  3. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
    2019 621 citations Marlon Perera, Nathan Papa et al. European Urology profile →
  4. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
    2018 339 citations Sue Ping Thang, Declan G. Murphy et al. Journal of Nuclear Medicine profile →
  5. Systematic Review and Cumulative Analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Cystectomy
    2015 303 citations Declan G. Murphy et al. European Urology profile →
  6. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
    2018 222 citations Shankar Siva, Declan G. Murphy et al. European Urology profile →
  7. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis
    2020 212 citations Niranjan Sathianathen, Declan G. Murphy et al. European Urology profile →
  8. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis
    2023 85 citations Wei Zheng So, Alvin Lee et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Declan G. Murphy Australia 49 6.6k 3.0k 2.1k 1.6k 1.3k 300 9.4k
Damien Bolton Australia 48 5.9k 0.9× 1.4k 0.5× 1.6k 0.8× 1.2k 0.7× 1.9k 1.4× 395 9.4k
Anthony V. D’Amico United States 57 13.2k 2.0× 1.8k 0.6× 2.6k 1.3× 2.4k 1.5× 2.4k 1.9× 361 16.4k
Scott E. Eggener United States 54 6.6k 1.0× 1.1k 0.4× 3.2k 1.6× 1.2k 0.7× 1.8k 1.4× 242 9.4k
Stacy Loeb United States 57 9.1k 1.4× 934 0.3× 2.4k 1.2× 2.3k 1.4× 1.9k 1.5× 443 13.3k
Jim C. Hu United States 57 7.2k 1.1× 808 0.3× 2.9k 1.4× 2.7k 1.7× 1.9k 1.4× 357 11.7k
Henk G. van der Poel Netherlands 54 7.6k 1.2× 1.9k 0.6× 4.4k 2.1× 2.1k 1.3× 2.7k 2.0× 412 13.2k
Joseph L. Chin Canada 51 6.9k 1.0× 1.5k 0.5× 2.9k 1.4× 2.2k 1.3× 1.4k 1.0× 340 11.1k
Antonio Finelli Canada 56 7.4k 1.1× 1.3k 0.4× 3.3k 1.6× 1.8k 1.1× 931 0.7× 477 11.2k
Paul L. Nguyen United States 62 9.6k 1.5× 1.9k 0.6× 2.8k 1.3× 4.8k 2.9× 1.0k 0.8× 558 16.6k
Matthew R. Cooperberg United States 68 15.0k 2.3× 1.8k 0.6× 4.0k 1.9× 4.0k 2.4× 2.1k 1.6× 539 19.0k

Countries citing papers authored by Declan G. Murphy

Since Specialization
Citations

This map shows the geographic impact of Declan G. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Declan G. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Declan G. Murphy more than expected).

Fields of papers citing papers by Declan G. Murphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Declan G. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Declan G. Murphy. The network helps show where Declan G. Murphy may publish in the future.

Co-authorship network of co-authors of Declan G. Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Declan G. Murphy. A scholar is included among the top collaborators of Declan G. Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Declan G. Murphy. Declan G. Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perera, Marlon, Joseph Ischia, Declan G. Murphy, et al.. (2025). Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies. British Journal of Urology. 136(5). 788–799. 1 indexed citations
2.
Chen, David C., Nathan Papa, Shankar Siva, et al.. (2025). Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta‐analysis. British Journal of Urology. 135(5). 720–732. 4 indexed citations
3.
Lindsay, Daniel, Penelope Schofield, Dorean Nabukalu, et al.. (2024). The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis. Australian Health Review. 48(2). 172–181.
4.
Ali, Muhammad, Kendrick Koo, Daniel Moon, et al.. (2024). Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. Radiation Oncology. 19(1). 23–23. 2 indexed citations
5.
6.
So, Wei Zheng, Alvin Lee, Dominic Wei Ting Yap, et al.. (2023). Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. European Urology. 84(1). 36–48. 85 indexed citations breakdown →
7.
8.
Ho, Mei‐Fong, Mehfuz Zaman, Emily Cooper, et al.. (2023). A CAF01-adjuvanted whole asexual blood-stage liposomal malaria vaccine induces a CD4 + T-cell-dependent strain-transcending protective immunity in rodent models. mBio. 14(6). e0254723–e0254723. 1 indexed citations
9.
Roberts, Matthew J., George Hruby, Andrew Kneebone, et al.. (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. British Journal of Urology. 132(2). 146–148. 2 indexed citations
10.
Sathianathen, Niranjan, Nathan Lawrentschuk, Badrinath R. Konety, et al.. (2023). Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?. European Urology Oncology. 7(4). 870–876. 5 indexed citations
11.
Emmett, Louise, Nathan Papa, James P Buteau, et al.. (2022). The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.. Journal of Nuclear Medicine. 63(11). jnumed.121.263448–jnumed.121.263448. 68 indexed citations
12.
13.
Nzenza, Tatenda, Renu Eapen, Nieroshan Rajarubendra, et al.. (2020). Review of the use of prophylactic drain tubes post‐robotic radical prostatectomy: Dogma or decent practice?. BJUI Compass. 1(4). 122–125. 6 indexed citations
14.
15.
Hyatt, Amelia, Ruby Lipson‐Smith, Meinir Krishnasamy, et al.. (2019). Testing Consultation Recordings in a Clinical Setting With the SecondEars Smartphone App: Mixed Methods Implementation Study. JMIR mhealth and uhealth. 8(1). e15593–e15593. 16 indexed citations
16.
17.
Sathianathen, Niranjan, Robert H. Lane, B. Condon, et al.. (2019). Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score. European Urology Focus. 6(3). 458–462. 13 indexed citations
18.
Sathianathen, Niranjan, et al.. (2017). Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective. Urological Science. 28(4). 190–196. 7 indexed citations
19.
Borgmann, Hendrik, Stacy Loeb, Johannes Salem, et al.. (2016). Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urologic Oncology Seminars and Original Investigations. 34(9). 377–383. 40 indexed citations
20.
Wootten, Addie, Jo-Anne Abbott, Denny Meyer, et al.. (2014). My road ahead : Results from an RCT evaluating an online psychological support program for men with prostate cancer. Deakin Research Online (Deakin University).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Damien Bolton Breakdown of academic impact, for papers by Anthony V. D’Amico Breakdown of academic impact, for papers by Scott E. Eggener Breakdown of academic impact, for papers by Stacy Loeb Breakdown of academic impact, for papers by Jim C. Hu Breakdown of academic impact, for papers by Henk G. van der Poel Breakdown of academic impact, for papers by Joseph L. Chin Breakdown of academic impact, for papers by Antonio Finelli Breakdown of academic impact, for papers by Paul L. Nguyen Breakdown of academic impact, for papers by Matthew R. Cooperberg
Rankless by CCL
2026